Last reviewed · How we verify
Spectrum Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| VLI | VLI | marketed | Vinca alkaloid | β-tubulin | Oncology | |
| SPI-2012 | SPI-2012 | phase 3 | PLK1 inhibitor | PLK1 (Polo-like kinase 1) | Oncology |
Therapeutic area mix
- Oncology · 3
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
- Polaryx Therapeutics, Inc. · 1 shared drug class
- Universität des Saarlandes · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Spectrum Pharmaceuticals, Inc:
- Spectrum Pharmaceuticals, Inc pipeline updates — RSS
- Spectrum Pharmaceuticals, Inc pipeline updates — Atom
- Spectrum Pharmaceuticals, Inc pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Spectrum Pharmaceuticals, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/spectrum-pharmaceuticals-inc. Accessed 2026-06-10.